Welcome to our dedicated page for Danaher news (Ticker: DHR), a resource for investors and traders seeking the latest updates and insights on Danaher stock.
Danaher Corporation reports developments tied to its global life sciences and diagnostics businesses, where its companies provide scientific technologies, clinical diagnostic systems and tools used in discovery, diagnosis and therapy development. Recurring updates include earnings calls, dividend actions, investor conference appearances and product or regulatory milestones from operating businesses such as Beckman Coulter Diagnostics.
Company news also covers diagnostic assays, immunoassay analyzer platforms, clinical-laboratory workflows and the Danaher Business System, which the company uses as an operating framework across its businesses. Additional recurring themes include shareholder voting matters, governance updates and capital-structure disclosures.
Danaher (NYSE: DHR) has announced an investment partnership with Innovaccer Inc., a healthcare AI company, through its subsidiaries Danaher Diagnostics and Danaher Ventures. The partnership aims to enhance patient outcomes through digital and diagnostic solutions.
Innovaccer has developed software solutions that create unified patient records to identify care gaps and at-risk patients. The collaboration seeks to accelerate precision diagnostics adoption among clinicians and population health teams, supporting value-based care initiatives.
The partnership aligns with Danaher's mission to advance precision medicine through AI-enabled diagnostics, focusing on providing healthcare providers with data and analytics for faster clinical insights at the point of need.
Danaher (NYSE: DHR) has announced its participation in the upcoming J.P. Morgan Healthcare Conference in San Francisco. The company's President and CEO, Rainer M. Blair, will deliver a presentation on Tuesday, January 14, 2025 at 11:15 a.m. PT.
The presentation will be accessible to the public through a simultaneous webcast, which can be viewed on Danaher's website in the 'Investors' section under 'Events & Presentations' at www.danaher.com.
Danaher (NYSE: DHR) has announced its upcoming fourth quarter 2024 earnings conference call, scheduled for Wednesday, January 29, 2025, at 8:00 a.m. ET. The hour-long call will discuss financial performance and future expectations.
The presentation will be accessible through a webcast on Danaher's website's 'Investors' section under 'Events & Presentations.' Participants can join via phone by dialing 800-445-7795 (U.S.) or +1 785-424-1699 (international).
The earnings press release and presentation materials will be available on the company's website at 6:00 a.m. ET on the call date. A replay will be accessible until February 12, 2025, through both the website and dial-in options.
Danaher (NYSE: DHR) has announced that its Board of Directors approved a regular quarterly cash dividend of $0.27 per share of common stock. The dividend will be paid on January 31, 2025 to shareholders who are registered as holders of record on December 27, 2024.
Danaher (NYSE: DHR) has announced that their President and CEO, Rainer M. Blair, will deliver a presentation at the Evercore ISI HealthCONx Conference. The event is scheduled to take place in Coral Gables, Florida on Wednesday, December 4, 2024, at 3:25 p.m. ET. Interested parties can access a simultaneous webcast of the presentation through the company's website at www.danaher.com.
Danaher (NYSE: DHR) reported its third quarter 2024 results, with net earnings of $818 million, or $1.12 per diluted common share. Non-GAAP adjusted diluted net earnings per common share were $1.71. Revenues increased 3.0% year-over-year to $5.8 billion, while non-GAAP core revenue increased 0.5%. Operating cash flow was $1.5 billion, and non-GAAP free cash flow was $1.2 billion.
CEO Rainer M. Blair highlighted strong performance, particularly in the bioprocessing business, and noted Cepheid's market share gains in molecular testing. For Q4 2024, Danaher anticipates non-GAAP core revenue to decline low-single digits year-over-year. The full year 2024 outlook remains unchanged, with non-GAAP core revenue expected to be down low-single digits year-over-year.
Danaher (NYSE: DHR) has announced its upcoming third quarter 2024 earnings conference call, scheduled for Tuesday, October 22, 2024, at 8:00 a.m. ET. The call, expected to last about an hour, will cover the company's financial performance and future expectations. Investors can access the webcast and accompanying slide presentation on Danaher's website under the 'Investors' section.
Participants can join the call by dialing 800-245-3047 within the U.S. or +1 203-518-9765 outside the U.S. (Conference ID: DHRQ324). A replay will be available until November 5, 2024. The earnings press release, webcast slides, and related materials will be posted on the company's website at 6:00 a.m. ET on the day of the call.
Beckman Coulter and Scopio Labs have expanded their partnership to include a global distribution agreement for Scopio's Full-Field Bone Marrow Aspirate™ (FF-BMA) Application. This CE-Marked technology transforms bone marrow aspirate analysis by combining high-resolution Full-Field imaging with AI-powered decision support, integrated with Scopio's X100 and X100HT scanners. The application enables remote review of bone marrow smears, potentially reducing turnaround time and improving diagnostic confidence.
This expansion builds on their existing collaboration since 2022 to accelerate the adoption of digital cell morphology. In 2023, Beckman Coulter announced an end-to-end automated hematology solution connecting its DxH 900 Workcell and DxH Slidemaker Stainer II with Scopio's X100HT platform for AI-assisted peripheral blood smear analysis.
Danaher (NYSE: DHR) has announced a regular quarterly cash dividend of $0.27 per share of its common stock. The dividend is payable on October 25, 2024 to shareholders of record as of September 27, 2024. This announcement demonstrates Danaher's commitment to returning value to its shareholders through consistent dividend payments. The quarterly dividend reflects the company's financial stability and confidence in its cash flow generation capabilities.
Danaher (NYSE: DHR) has reaffirmed its previously issued guidance for the third quarter and full year 2024. The company expects non-GAAP core revenue to decline by low-single digits year-over-year for both periods. This confirmation comes ahead of a scheduled analyst event on September 5, 2024, in Washington, D.C., hosted by Julie Sawyer Montgomery, Executive Vice President of Diagnostics.
Danaher provides forecasts only on a non-GAAP core revenue basis due to difficulties in estimating other GAAP revenue components such as currency translation, acquisitions, and divested product lines. The analyst meeting will be webcast on Danaher's website, with a replay available after the presentation.